Alabama Oncology | Research department

Research site

(Unclaimed)

Location

500 Office Park Drive , suite 400, Birmingham, Alabama, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Bevacizumab

Carboplatin

Lenalidomide

Gemcitabine

Sacituzumab

Leucovorin

Oxaliplatin

PEGPH20

5-FU

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 30 total trials

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (CodeBreaK201)

The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (REC...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Sotorasib

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in comb...

Active, not recruiting

Multiple Myeloma

Drug: Lenalidomide

Drug: Bortezomib

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3)

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will stu...

Active, not recruiting

Diffuse Large B-cell Lymphoma

Drug: Rituximab

Drug: Lenalidomide

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective:To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrin...

Active, not recruiting

Breast Cancer Metastatic

Drug: Tamoxifen

Drug: Anastrozole

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling

Triple Negative Breast Cancer

Drug: Capecitabine

Drug: Sacituzumab govitecan-hziy (SG)

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in...

Enrolling

Extensive Stage Small Cell Lung Cancer

Drug: Serplulimab + chemotherapy (carboplatin-etoposide)

Drug: Atezolizumab + chemotherapy (carboplatin-etoposide)